A study by researchers at the UCLA Jonsson Comprehensive Cancer Center found that using percutaneous image guided needle based thermal ablation is a safe and effective adjunctive therapy for the local control of metastatic gynecologic cancers throughout lungs, liver, soft tissues in the abdomen and pelvis and bones—and in patients with advanced localized cancers unresponsive to systemic therapy.
Long-term, regular use of baby aspirin-at least 15 times per month-prior to a diagnosis of colorectal cancer may reduce the risk of death from the disease by limiting the spread of cancerous tumors pre-diagnosis, according to a study led by Cedars-Sinai Cancer researchers.
A phase III trial evaluating Keytruda (pembrolizumab) plus Lenvima (lenvatinib) in certain patients with advanced, metastatic or recurrent endometrial cancer following one prior platinum-based regimen in any setting met its dual primary endpoints of progression-free survival and overall survival.
The phase III IMpower010 study evaluating Tecentriq (atezolizumab) compared with best supportive care met its primary endpoint of disease-free survival at the interim analysis.
The phase II/III RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma met its primary endpoint of progression-free survival.
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
SignalChem Lifesciences, and a subsidiary of Merck, are evaluating the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer.
Even with access to a clinical trial, cancer patients living in the poorest neighborhoods in America have a nearly 30% greater chance of dying from their disease compared to the wealthiest patients, SWOG Cancer Research Network study results show.
ILLUMINATE-301, the registration trial of tilsotolimod in combination with Yervoy (ipilimumab) versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate.
Aveo Oncology and Bristol Myers Squibb are collaborating on a phase III clinical trial to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab) in patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.
